Mode of interaction of loop diuretics with human serum albumin and characterization of binding site

被引:26
作者
Takamura, N
Haruta, A
Kodama, H
Tsuruoka, M
Yamasaki, K
Suenaga, A
Otagiri, M
机构
[1] KUMAMOTO UNIV,FAC PHARMACEUT SCI,KUMAMOTO 862,JAPAN
[2] MIYAZAKI MED COLL HOSP,DEPT PHARM,KIYOTAKE,MIYAZAKI 88916,JAPAN
关键词
warfarin binding region; loop diuretics; human serum albumin; binding site; displacement;
D O I
10.1023/A:1016098305796
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The purpose of this study was to investigate the binding mechanism of loop diuretics with HSA and to characterize the binding site on HSA. Methods. Quantitative analysis of potential interaction between ligands bound to HSA was performed by equilibrium dialysis and data for binding of the two ligands to HSA were analyzed on the basis of a theoretical model of simultaneous binding of two ligands. Results. The binding of loop diuretics is dependent upon the N-B transition, conformational change of albumin. Furthermore, from the results of binding of the drugs to modified HSA, the lysine residue seems to be involved in the binding of loop diuretics to HSA. Conclusions. Analysis using models describing independent, competitive, cooperative and anti-cooperative binding led to the conclusion that loop diuretics bind to site I, particularly to the warfarin region on HSA.
引用
收藏
页码:1015 / 1019
页数:5
相关论文
共 15 条
[1]  
BOS OJM, 1989, J BIOL CHEM, V264, P953
[2]  
CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153
[3]   THE LOCATION OF DRUG-BINDING SITES IN HUMAN-SERUM ALBUMIN [J].
FEHSKE, KJ ;
MULLER, WE ;
WOLLERT, U .
BIOCHEMICAL PHARMACOLOGY, 1981, 30 (07) :687-692
[4]   MODIFICATION OF HUMAN-SERUM ALBUMIN WITH TRIFLUOROMETHYL-SUBSTITUTED ARYL HALIDES AND SULFONATES [J].
GERIG, JT ;
REINHEIMER, JD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1975, 97 (01) :168-173
[5]   INTERACTION BETWEEN DRUGS AND BLOOD COMPONENTS .7. BINDING OF SEVERAL LOOP DIURETICS TO SERUM-ALBUMIN AND HUMAN-SERUM FROM PATIENTS WITH RENAL-FAILURE AND LIVER-DISEASE [J].
GOTO, S ;
YOSHITOMI, H ;
MIYAMOTO, A ;
INOUE, K ;
NAKANO, M .
JOURNAL OF PHARMACOBIO-DYNAMICS, 1980, 3 (12) :667-676
[6]  
JUSCO WJ, 1976, DRUG METAB REV, V5, P43
[7]  
KRAGHHANSEN U, 1981, PHARMACOL REV, V33, P17
[8]   A NATURALLY-OCCURRING FURAN FATTY-ACID ENHANCES DRUG-INHIBITION OF THYROXINE-BINDING IN SERUM [J].
LIM, CF ;
STOCKIGT, JR ;
CURTIS, AJ ;
WYNNE, KN ;
BARLOW, JW ;
TOPLISS, DJ .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1993, 42 (11) :1468-1474
[9]  
Sakai T, 1995, BIOL PHARM BULL, V18, P1755
[10]  
SUDLOW G, 1976, MOL PHARMACOL, V12, P1052